28390176|t|Cucurbitacin B Protects Against Pressure Overload Induced Cardiac Hypertrophy
28390176|a|Lack of effective anti-cardiac hypertrophy drugs creates a major cause for the increasing prevalence of heart failure. In the present study, we determined the anti-hypertrophy and anti-fibrosis potential of a natural plant triterpenoid, Cucurbitacin B both in vitro and in vivo. Aortic banding (AB) was performed to induce cardiac hypertrophy. After 1 week of surgery, mice were receive cucurbitacin B treatment (Gavage, 0.2 mg/kg body weight /2 day). After 4 weeks of AB, cucurbitacin B demonstrated a strong anti-hypertrophy and -fibrosis ability as evidenced by decreased of heart weight, myocardial cell cross-sectional area and interstitial fibrosis, ameliorated of systolic and diastolic abnormalities, normalized in gene expression of hypertrophic and fibrotic markers, reserved microvascular density in pressure overload induced hypertrophic mice. Cucurbitacin B also showed significant hypertrophy inhibitory effect in phenylephrine stimulated cardiomyocytes. The Cucurbitacin B -mediated mitigated cardiac hypertrophy was attributable to the increasing level of autophagy, which was associated with the blockade of Akt / mTOR / FoxO3a signal pathway, validated by SC79, MK2206, and 3-MA, the Akt agonist, inhibitor and autophagy inhibitor in vitro. The overexpression of constitutively active Akt completely abolished the Cucurbitacin B -mediated protection of cardiac hypertrophy in human cardiomyocytes AC16. Collectively, our findings suggest that cucurbitacin B protects against cardiac hypertrophy through increasing the autophagy level in cardiomyocytes, which is associated with the inhibition of Akt / mTOR / FoxO3a signal axis. J. Cell. Biochem. 9999: 1-12, 2017. Â© 2017 Wiley Periodicals, Inc.
28390176	0	14	Cucurbitacin B	T109,T121	C0056580
28390176	32	40	Pressure	T184	C0497233
28390176	41	49	Overload	UnknownType	C0684338
28390176	58	77	Cardiac Hypertrophy	T046	C1383860
28390176	96	126	anti-cardiac hypertrophy drugs	T121	C1254351
28390176	143	148	cause	T169	C0015127
28390176	168	178	prevalence	T081	C0033105
28390176	182	195	heart failure	T047	C0018801
28390176	237	253	anti-hypertrophy	T033	C0243095
28390176	258	271	anti-fibrosis	T033	C0243095
28390176	272	281	potential	T080	C3245505
28390176	287	300	natural plant	T002	C0032098
28390176	301	313	triterpenoid	T109	C1519655
28390176	315	329	Cucurbitacin B	T109,T121	C0056580
28390176	335	343	in vitro	T062	C0681828
28390176	348	355	in vivo	T062	C0681829
28390176	357	371	Aortic banding	T061	C0185014
28390176	373	375	AB	T061	C0185014
28390176	401	420	cardiac hypertrophy	T046	C1383860
28390176	438	445	surgery	T061	C0543467
28390176	447	451	mice	T015	C0025929
28390176	465	479	cucurbitacin B	T109,T121	C0056580
28390176	480	489	treatment	T061	C0087111
28390176	491	497	Gavage	T169	C2698653
28390176	509	520	body weight	T032	C0005910
28390176	547	549	AB	T061	C0185014
28390176	551	565	cucurbitacin B	T109,T121	C0056580
28390176	588	604	anti-hypertrophy	T033	C0243095
28390176	609	618	-fibrosis	T033	C0243095
28390176	656	661	heart	T023	C0018787
28390176	662	668	weight	T081	C0043100
28390176	670	685	myocardial cell	T025	C0225828
28390176	686	706	cross-sectional area	T201	C2923394
28390176	711	732	interstitial fibrosis	T046	C0240035
28390176	749	757	systolic	T079	C0039155
28390176	762	771	diastolic	T201	C0012000
28390176	772	785	abnormalities	T033	C0205161
28390176	801	816	gene expression	T045	C0017262
28390176	820	832	hypertrophic	T046	C0020564
28390176	837	845	fibrotic	T169	C0334129
28390176	846	853	markers	T201	C0005516
28390176	864	885	microvascular density	T080	C3272839
28390176	889	897	pressure	T184	C0497233
28390176	898	906	overload	UnknownType	C0684338
28390176	915	927	hypertrophic	T046	C0020564
28390176	928	932	mice	T015	C0025929
28390176	934	948	Cucurbitacin B	T109,T121	C0056580
28390176	973	984	hypertrophy	T046	C0020564
28390176	985	1002	inhibitory effect	T033	C0243095
28390176	1006	1019	phenylephrine	T109,T121	C0031469
28390176	1020	1030	stimulated	T070	C1948023
28390176	1031	1045	cardiomyocytes	T025	C0225828
28390176	1051	1065	Cucurbitacin B	T109,T121	C0056580
28390176	1076	1085	mitigated	T067	C1553901
28390176	1086	1105	cardiac hypertrophy	T046	C1383860
28390176	1150	1159	autophagy	T043	C0004391
28390176	1171	1186	associated with	T080	C0332281
28390176	1191	1199	blockade	T169	C0332206
28390176	1203	1206	Akt	T116,T126	C0164786
28390176	1209	1213	mTOR	T116,T126	C1453984
28390176	1216	1222	FoxO3a	T116,T123	C1506134
28390176	1223	1237	signal pathway	T044	C0037080
28390176	1252	1256	SC79	T109	C4307495
28390176	1258	1264	MK2206	T109,T121	C2933427
28390176	1270	1274	3-MA	T114	C0047569
28390176	1280	1283	Akt	T116,T126	C0164786
28390176	1284	1291	agonist	T121	C2987634
28390176	1293	1302	inhibitor	T120	C0243077
28390176	1307	1316	autophagy	T043	C0004391
28390176	1317	1326	inhibitor	T120	C0243077
28390176	1327	1335	in vitro	T062	C0681828
28390176	1341	1355	overexpression	T045	C1514559
28390176	1381	1384	Akt	T116,T126	C0164786
28390176	1410	1424	Cucurbitacin B	T109,T121	C0056580
28390176	1449	1468	cardiac hypertrophy	T046	C1383860
28390176	1472	1477	human	T016	C0086418
28390176	1478	1497	cardiomyocytes AC16	T025	C0225828
28390176	1539	1553	cucurbitacin B	T109,T121	C0056580
28390176	1571	1590	cardiac hypertrophy	T046	C1383860
28390176	1614	1623	autophagy	T043	C0004391
28390176	1633	1647	cardiomyocytes	T025	C0225828
28390176	1658	1673	associated with	T080	C0332281
28390176	1678	1688	inhibition	T043	C1519312
28390176	1692	1695	Akt	T116,T126	C0164786
28390176	1698	1702	mTOR	T116,T126	C1453984
28390176	1705	1711	FoxO3a	T116,T123	C1506134
28390176	1712	1723	signal axis	T044	C0037080